BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23937544)

  • 1. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
    Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
    J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 5-(3-Chlorophenylamino)benzo[
    Wang Y; Lv Z; Chen F; Wang X; Gou S
    J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel CK2 leads by cross-docking based virtual screening.
    Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
    Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
    Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
    Molecules; 2017 May; 22(5):. PubMed ID: 28534839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
    Wang X; Pan P; Li Y; Li D; Hou T
    Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
    Vahter J; Viht K; Uri A; Enkvist E
    Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
    Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
    Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase CK2 inhibition: an update.
    Cozza G; Pinna LA; Moro S
    Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
    Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
    Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.
    Haddach M; Pierre F; Regan CF; Borsan C; Michaux J; Stefan E; Kerdoncuff P; Schwaebe MK; Chua PC; Siddiqui-Jain A; Macalino D; Drygin D; O'Brien SE; Rice WG; Ryckman DM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):45-8. PubMed ID: 22169261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
    Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
    Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of CX-4945 binding to human protein kinase CK2.
    Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
    FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening.
    Nakanishi I; Murata K; Nagata N; Kurono M; Kinoshita T; Yasue M; Miyazaki T; Takei Y; Nakamura S; Sakurai A; Iwamoto N; Nishiwaki K; Nakaniwa T; Sekiguchi Y; Hirasawa A; Tsujimoto G; Kitaura K
    Eur J Med Chem; 2015; 96():396-404. PubMed ID: 25912672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
    Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.